Evidence Table 75. KQ2—Continuous data—C-reactive protein

| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mabuchi 200739parallel | Unclear | atorvastatin | 1 | Coenzyme Q10. | 24 | NR | Mean: 799Median SD: 1209SE:Lower: Upper: | Mean:% mean: -46.8Median:SD:0.5408P: | Mean:Median:SD:P: | There's no significant differences between groups (p=0.5943). Several other continuous outcomes, such as alkaline phosphatase, LDH, CoQ10/ total cholesterol and CoQ10/LDL were not extracted. | medium |
|  |  Placebo | 25 | Mean:777Median SD: 1038SE:Lower: Upper: | Mean:% mean: -14.6Median:SD:P:0.8743 |

| Evidence Table 75. KQ2—Continuous data—C-reactive protein (continued) |
| --- |
| **Author Year****Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/****(Median)****SD/SE****Lower limit (IQR, 95% CI)****Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/****SD/****P Value** | **Between group differences in Means/ medians****SD/****P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Budoff 200410parallel | At high risk for CHD | statins + aspirin | 10-40 | Garlic | 9 | measured after 12 hr fast at 800 hr | Mean: Median SD: SE:Lower: Upper: | Mean:-0.1% mean: Median:SD:0.22P: | Mean:Median:SD:P:0.8464 |  | medium |
|  | Placebo | 10 | Mean:Median SD: SE:Lower: Upper: | Mean:-0.13Median:SD:0.27P: |
| Chan 200212parallel | At moderate/moderately high risk for CHD (2+ risk factors) | atorvastatin | 40 | Fish/marine oils.  | 11 | 12 hr fasting at 800hr | Mean: 1.14Median SD: 1.97SE:Lower: 0.6Upper: 2.4 | Mean:% mean: Median:SD:P: | Mean:Median:SD:P: |  | medium |
|  | Placebo | 13 | Mean:Median SD: SE:Lower: 1.1Upper:4 | Mean:Median:SD:P: |
| Desideri 200318parallel | At low risk for CHD (0-1 risk factors) | Simvastatinstatin, Bezafibrate | simvastatinstatin: 40; Bezafibrate: 800 | Vitamin E.  |  | Measured after 12 hr fast | Mean: 1.5Median SD: 0.4SE:Lower: Upper: | Mean:% mean: Median:SD:P:<0.05 | Mean:Median:SD:P: | I assumed no losses to follow-up although I did not see this explicitely stated. Baseline data also given. | medium |
|  |  No treatment (aside from CVD drug) |  | Mean:1.9Median SD: 0.3SE:Lower: Upper: | Mean:Median:SD:P:<0.05 |
|  |  |  | Mean:Median SD: SE:Lower: Upper: | Mean:Median:SD:P: |